These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 29214365)

  • 1. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
    Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
    PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.
    Doebar SC; Sieuwerts AM; de Weerd V; Stoop H; Martens JWM; van Deurzen CHM
    Am J Pathol; 2017 Jul; 187(7):1648-1655. PubMed ID: 28634007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
    Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD
    Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
    Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
    Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.
    Hannafon BN; Sebastiani P; de las Morenas A; Lu J; Rosenberg CL
    Breast Cancer Res; 2011 Mar; 13(2):R24. PubMed ID: 21375733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype-specific micro-RNA expression signatures in breast cancer progression.
    Haakensen VD; Nygaard V; Greger L; Aure MR; Fromm B; Bukholm IR; Lüders T; Chin SF; Git A; Caldas C; Kristensen VN; Brazma A; Børresen-Dale AL; Hovig E; Helland Å
    Int J Cancer; 2016 Sep; 139(5):1117-28. PubMed ID: 27082076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
    Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
    Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
    Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.
    Lee S; Stewart S; Nagtegaal I; Luo J; Wu Y; Colditz G; Medina D; Allred DC
    Cancer Res; 2012 Sep; 72(17):4574-86. PubMed ID: 22751464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
    Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
    Woo JW; Choi HY; Kim M; Chung YR; Park SY
    Breast Cancer; 2022 Sep; 29(5):814-824. PubMed ID: 35451796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.